Prostate cancer Board decisions

The Board granted service connection for autoimmune hepatitis and prostate cancer based on new evidence showing a relationship to toxic exposure during service.

The Board denied the Veteran's claims for earlier effective dates for service connection for prostate cancer, erectile dysfunction, and CAD, as these were granted under the PACT Act on August 10, 2022.

The Board denied the Veteran's claims for service connection for kidney cancer and prostate cancer, as there was no evidence of exposure to ionizing radiation during active service.

The Board granted a 60 percent disability rating for prostate cancer residuals/neurogenic bladder from July 12, 2018, to January 29, 2024, and denied a higher rating. The issues of service connection for fecal incontinence, right upper extremity tendonitis, left upper extremity tendonitis, right lower extremity tendonitis, and left lower extremity tendonitis were remanded.

The Board granted an effective date of October 7, 2020, for the award of service connection for bladder and prostate cancers due to presumed exposure to herbicide agent under the PACT Act.

The Board denied service connection for diabetes mellitus (DM) type II and prostate cancer, finding no evidence of in-service incurrence or a causal relationship to the Veteran's service.

The Board has dismissed the appeals for service connection for prostate cancer and kidney cancer as the Veteran withdrew his claims.

The appeal of the proposed reduction in the evaluation of prostate cancer from 100 percent disabling to noncompensable (0 percent) is dismissed.

The appeal of the proposed reduction of the Veteran's disability rating for prostate cancer was dismissed as it is not a decision that can be appealed to the Board.

The Board denied the Veteran's claim for service connection for prostate cancer with voiding dysfunction, finding that the evidence does not support a link between the condition and active duty service.

The Board granted readjudication of the previously denied claim for prostate cancer and denied it for tinnitus, with the prostate cancer issue remanded for further development.

The Board denied service connection for the cause of the Veteran's death, as there was no evidence that his prostate cancer was related to his military service.

The Board granted service connection for prostate cancer, which is presumed to be related to the Veteran's exposure to herbicides during his service in Vietnam.

The Board denied the Veteran's claim for service connection for a prostate disability, including BPH and prostate cancer, as there is no current diagnosis of prostate cancer and the Veteran's BPH is not related to his service.

The Board granted restoration of service connection for right middle finger laceration scar, prostate cancer surgical scar, erectile dysfunction, PTSD, malignant neoplasms of the prostate with radical prostatectomy and residual urinary incontinence due to agent orange exposure, tinnitus, bilateral hearing loss, and special monthly compensation for loss of use of a creative organ.

The Board granted service connection for prostate cancer, diabetes mellitus, Type II (DM II), and hypertension (HTN) based on the appellant's exposure to herbicide agents during his service in Vietnam.

The Board dismissed the claims for service connection for stricture of esophagus, right knee disability, and denied the claim for service connection for prostate cancer. The appeal for a higher rating for tinnitus was also denied.

The Board remands the claims for service connection for bladder cancer, an acquired psychiatric disorder, prostate cancer, urinary incontinence, and urinary tract infection due to a need for additional evidence.

The Board remanded the veteran's claims for service connection of prostate cancer, colon cancer, and traumatic brain injury (TBI), as well as special monthly compensation. The decision was based on new evidence and the need for further development.

The veteran's claim for a higher disability rating for prostate cancer was denied. Service connection for constipation/hemorrhoids was granted. The claim for TDIU prior to August 21, 2014, was remanded.